GSI to acquire NDS Surgical Imaging

Editorial Staff | | Health Imaging | Artificial Intelligence

GSI Group has acquired San Jose, Calif.-based NDS Surgical Imaging (NDSsi) for $82.5 million in cash, subject to customary closing adjustments.

GSI Group is a supplier of laser-based, precision motion and optical technologies, and the acquisition was the result of its medical component market strategy, according to the Bedford, Mass.-based company.

The total purchase price is financed using approximately $25 million of cash on-hand with the remainder from GSI Group’s credit facility. The acquisition closed as of Tuesday, Jan. 15, according to a GSI Group press release. The transaction is earnings accretive and is expected to add more than $80 million in revenue and nearly $12 million of adjusted earnings before interest, taxes, depreciation and amortization to GSI’s financial results in 2013, according to the company.

Editorial Staff

Related Content

AI beats standard regression models at predicting lung cancer risk
AI reduces CT lung cancer screening workload by nearly 80%
How AI and CCTA help heart teams plan ahead before PCI
5 steps for evaluating radiology AI applications
Adaptable AI system detects subtle changes in imaging, has potential across multiple clinical settings
New algorithm models radiologists' eye movements to interpret chest X-rays

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.